Pharsight

Sebela Ireland Ltd patents expiration

1. Brisdelle patents expiration

BRISDELLE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(1 year, 1 month from now)

US8946251 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(2 years from now)

US8658663 SEBELA IRELAND LTD Method of treating thermoregulatory disfunction with paroxetine
Apr, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393237 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(2 years from now)

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 28 June, 2013

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE;ORAL

How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage

BRISDELLE family patents

Family Patents

2. Naftin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166206 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10166205 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10729667 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US10695303 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US9161914 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

US8778365 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(8 years from now)

Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 June, 2013

Treatment: Treatment of fungal infections

Dosage: GEL;TOPICAL

How can I launch a generic of NAFTIN before it's drug patent expiration?
More Information on Dosage

NAFTIN family patents

Family Patents

3. Onmel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486456 SEBELA IRELAND LTD Itraconazole compositions with improved bioavailability
Oct, 2028

(4 years from now)

Drugs and Companies using ITRACONAZOLE ingredient

Market Authorisation Date: 29 April, 2010

Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks

Dosage: TABLET;ORAL

More Information on Dosage

ONMEL family patents

Family Patents

4. Pexeva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(1 year, 1 month from now)

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 03 July, 2003

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

PEXEVA family patents

Family Patents